Pro-AbbVie bias may be driving rheumatologist confidence in newcomer Rinvoq: analyst

Between AbbVie's blue-blood launch duo, psoriasis med Skyrizi's booming sales have drawn some analysts' eyes away from highly touted rheumatoid arthritis drug Rinvoq. But among physicians, Rinvoq is becoming a darling, one analyst said—and an "AbbVie halo" could be major part of that.